ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 127 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $377 | +13.9% | 14,739 | +27.7% | 0.00% | 0.0% |
| Q2 2023 | $331 | +32.4% | 11,539 | +10.5% | 0.00% | 0.0% |
| Q1 2023 | $250 | +46.2% | 10,439 | +2.9% | 0.00% | – |
| Q4 2022 | $171 | -99.9% | 10,140 | 0.0% | 0.00% | – |
| Q3 2022 | $150,000 | -10.7% | 10,140 | -5.5% | 0.00% | – |
| Q2 2022 | $168,000 | -41.9% | 10,727 | -0.2% | 0.00% | -100.0% |
| Q1 2022 | $289,000 | -30.0% | 10,752 | -3.8% | 0.00% | 0.0% |
| Q4 2021 | $413,000 | -21.0% | 11,172 | +2.0% | 0.00% | 0.0% |
| Q3 2021 | $523,000 | +33.4% | 10,954 | -5.6% | 0.00% | 0.0% |
| Q2 2021 | $392,000 | -3.4% | 11,607 | +17.8% | 0.00% | 0.0% |
| Q1 2021 | $406,000 | +5.5% | 9,849 | +11.0% | 0.00% | 0.0% |
| Q4 2020 | $385,000 | +66.7% | 8,875 | +64.5% | 0.00% | 0.0% |
| Q3 2020 | $231,000 | +11.1% | 5,396 | +21.0% | 0.00% | 0.0% |
| Q2 2020 | $208,000 | – | 4,461 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |